PUBLISHER: The Business Research Company | PRODUCT CODE: 1810901
PUBLISHER: The Business Research Company | PRODUCT CODE: 1810901
Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025
Gonadotropin-releasing hormone (GnRH) agonists and antagonists are synthetic drugs that control the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. GnRH agonists initially cause an increase in LH and FSH release but eventually lead to their suppression over time. In contrast, GnRH antagonists block GnRH receptors directly, resulting in an immediate reduction of hormone levels.
The primary types of gonadotropin-releasing hormone (GnRH) agonists and antagonists include GnRH agonists such as leuprorelin, goserelin, triptorelin, histrelin, and buserelin, as well as GnRH antagonists like degarelix and abarelix, among others. GnRH agonists mimic the natural hormone GnRH, triggering an initial release of LH and FSH from the pituitary gland, followed by hormone suppression with continued use, thereby reducing sex hormone production. These drugs are used in various fields, including gynecology and oncology, with key end users being hospitals, specialty clinics, and similar healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market statistics, including the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs industry's global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market share, detailed gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market. This gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size has grown strongly in recent years. It will grow from $1.57 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period was driven by a rising prevalence of hormone-related disorders, an increase in prostate and breast cancer cases, heightened awareness of reproductive health, growing demand for assisted reproductive technologies, and greater use of hormone therapies for conditions like endometriosis and uterine fibroids.
The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth during the forecast period is driven by a growing preference for minimally invasive treatment options, increased awareness of women's health concerns, expanded availability of combination therapies, improved healthcare access in developing regions, and a rising pipeline of novel drug formulations. Key trends expected to shape this period include progress in oral GnRH antagonist formulations, innovations in combination therapies featuring hormonal add-back, incorporation of digital health technologies for monitoring reproductive treatments, advancements in clinical trial designs to accelerate approvals, and the growing use of telemedicine in hormone therapy.
The rising incidence of ovarian and prostate cancers is expected to drive the growth of the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in the future. Ovarian and prostate cancers are hormone-sensitive tumors influenced by estrogen and testosterone and are frequently treated with hormone-regulating therapies such as GnRH agonists or antagonists. The increase in ovarian and prostate cancer cases is linked to longer life expectancy, as the risk of developing these hormone-sensitive cancers rises with age. GnRH agonists and antagonists help treat ovarian and prostate cancers by suppressing the production of sex hormones like estrogen and testosterone, which promote the growth of these tumors. For example, in 2023, Cancer Australia, a government agency, reported that around 1,786 new ovarian cancer cases are expected to be diagnosed in Australia. Additionally, women face approximately a 1 in 87 chance (or 1.2% risk) of being diagnosed with ovarian cancer by age 85. Thus, the increasing prevalence of ovarian and prostate cancers is fueling the growth of the GnRH agonists and antagonists drugs market.
Key players in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market are focusing on developing innovative treatments, such as oral GnRH receptor antagonists, to improve patient convenience, boost treatment adherence, and reduce reliance on injectable therapies. Oral GnRH receptor antagonists are pills that block GnRH receptors to rapidly decrease sex hormone levels, aiding in the treatment of hormone-related conditions like prostate cancer and endometriosis. For instance, in March 2024, Sumitomo Pharma Co. Ltd., a pharmaceutical company based in Japan, announced that ORGOVYX (relugolix), the first and only oral androgen deprivation therapy (ADT) for advanced prostate cancer, received approval from Health Canada and is now available in Canada. ORGOVYX is a once-daily oral GnRH receptor antagonist that suppresses testosterone production, a major factor in prostate cancer progression. Its approval was based on the Phase 3 HERO study, which showed effective and sustained testosterone suppression, a decrease in major cardiovascular events, and similar castration resistance-free survival compared to standard injectable treatments.
In February 2022, Debiopharm Group, a Switzerland-based biopharmaceutical company, partnered with Aspen Pharmacare Holdings Limited to improve treatment options for locally advanced and metastatic hormone-dependent prostate cancer. The collaboration aims to expand access to Debiopharm's GnRH drug, Trelstar, in South Africa, offering effective hormone therapy to patients with advanced prostate cancer by reducing testosterone levels and slowing disease progression. Aspen Pharmacare Holdings Limited is a South Africa-based manufacturer of gonadotropin-releasing hormone (GnRH) agonists.
Major players in the gonadotropin-releasing hormone (gnrh) agonists and antagonists drugs market are Pfizer Inc., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Intas Pharmaceuticals Limited, Sumitomo Pharma Co. Ltd., Ipsen S.A., Dr. Reddy's Laboratories Limited, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Zydus Lifesciences Limited, Gland Pharma Limited, Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Aska Pharmaceutical Co. Ltd., Ferring International Center S.A., Tolmar Inc., Debiopharm International SA, TerSera Therapeutics LLC, and TiumBio Co. Ltd.
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gonadotropin-releasing hormone (GnRH) agonist and antagonist drugs market consists of sales of injectable formulations, intranasal spray, subcutaneous implants, microsphere-based depot formulations, and ready-to-use prefilled syringes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gonadotropin-releasing hormone (GnRH) agonists and antagonists drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: GnRH Agonists; Leuprorelin; Goserelin; Triptorelin; Histrelin; Buserelin; GnRH Antagonists; Degarelix; Abarelix; Other Drug Types
- 2) By Application: Gynecology; Oncology; Other Applications
- 3) By End-User: Hospitals; Specialty Clinics; Other End-Users
- Subsegments:
- 1) By GnRH Agonists: Deslorelin; Gonadorelin; Zoladex Long-Acting Goserelin Variant; Lupron Depot-Ped; Sustained-Release Microsphere Formulations
- 2) By Leuprorelin: Depot Injection; Implant; Combination Therapy Formulations
- 3) By Goserelin: Subcutaneous Implant; Oncology-Specific Formulation; Gynecology-Specific Formulation
- 4) By Triptorelin: Intramuscular Injection; Long-Acting (1-, 3-, 6-Month) Depot; Fertility Treatment Formulation
- 5) By Histrelin: Subcutaneous Implant; Pediatric (Precocious Puberty) Formulation; Adult Prostate Cancer-Specific Version
- 6) By Buserelin: Nasal Spray; Subcutaneous Injection; In Vitro Fertilization And Fertility Cycle Formulations
- 7) By GnRH Antagonists: Teverelix DP; Elagolix; Relugolix; Ganirelix; Linzagolix
- 8) By Degarelix: Subcutaneous Injection; Monthly Dosing; Prostate Cancer-Specific Formulation
- 9) By Abarelix: Intramuscular Injection; Advanced Prostate Cancer; Short-Acting Formulation
- 10) By Other Drug Types: Subcutaneous Injection; In Vitro Fertilization-Specific Use; Multiple Dosing Regimens
- Companies Mentioned: Pfizer Inc.; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Merck KGaA; Intas Pharmaceuticals Limited; Sumitomo Pharma Co. Ltd.; Ipsen S.A.; Dr. Reddy's Laboratories Limited; Cipla Limited; Gedeon Richter Plc; Lupin Limited; Zydus Lifesciences Limited; Gland Pharma Limited; Bachem Holding AG; Kissei Pharmaceutical Co. Ltd.; Aska Pharmaceutical Co. Ltd.; Ferring International Center S.A.; Tolmar Inc.; Debiopharm International SA; TerSera Therapeutics LLC; TiumBio Co. Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Characteristics
3. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth Rate Analysis
- 5.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Total Addressable Market (TAM)
6. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Segmentation
- 6.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- GnRH Agonists
- Leuprorelin
- Goserelin
- Triptorelin
- Histrelin
- Buserelin
- GnRH Antagonists
- Degarelix
- Abarelix
- Other Drug Types
- 6.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gynecology
- Oncology
- Other Applications
- 6.3. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Other End-Users
- 6.4. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Deslorelin
- Gonadorelin
- Zoladex Long-Acting Goserelin Variant
- Lupron Depot-Ped
- Sustained-Release Microsphere Formulations
- 6.5. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Depot Injection
- Implant
- Combination Therapy Formulations
- 6.6. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Goserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous Implant
- Oncology-Specific Formulation
- Gynecology-Specific Formulation
- 6.7. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intramuscular Injection
- Long-Acting (1-, 3-, 6-Month) Depot
- Fertility Treatment Formulation
- 6.8. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous Implant
- Pediatric (Precocious Puberty) Formulation
- Adult Prostate Cancer-Specific Version
- 6.9. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Buserelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nasal Spray
- Subcutaneous Injection
- In Vitro Fertilization And Fertility Cycle Formulations
- 6.10. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of GnRH Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Teverelix DP
- Elagolix
- Relugolix
- Ganirelix
- Linzagolix
- 6.11. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Degarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous Injection
- Monthly Dosing
- Prostate Cancer-Specific Formulation
- 6.12. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Abarelix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intramuscular Injection
- Advanced Prostate Cancer
- Short-Acting Formulation
- 6.13. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Subcutaneous Injection
- In Vitro Fertilization-Specific Use
- Multiple Dosing Regimens
7. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Regional And Country Analysis
- 7.1. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 8.1. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 9.1. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 9.2. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 10.1. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 11.1. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 11.2. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 12.1. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 13.1. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 14.1. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 14.2. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 15.1. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 15.2. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 16.1. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 17.1. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 18.1. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 19.1. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 20.1. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 21.1. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 21.2. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 22.1. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 23.1. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 23.2. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 24.1. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 24.2. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 25.1. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 25.2. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 26.1. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 26.2. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 27.1. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 28.1. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 28.2. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
- 29.1. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Overview
- 29.2. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Landscape And Company Profiles
- 30.1. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Landscape
- 30.2. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
31. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Other Major And Innovative Companies
- 31.1. Intas Pharmaceuticals Limited
- 31.2. Sumitomo Pharma Co. Ltd.
- 31.3. Ipsen S.A.
- 31.4. Dr. Reddy's Laboratories Limited
- 31.5. Cipla Limited
- 31.6. Gedeon Richter Plc
- 31.7. Lupin Limited
- 31.8. Zydus Lifesciences Limited
- 31.9. Gland Pharma Limited
- 31.10. Bachem Holding AG
- 31.11. Kissei Pharmaceutical Co. Ltd.
- 31.12. Aska Pharmaceutical Co. Ltd.
- 31.13. Ferring International Center S.A.
- 31.14. Tolmar Inc.
- 31.15. Debiopharm International SA
32. Global Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
34. Recent Developments In The Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market
35. Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
